AUS-131 is under clinical development by MEI Pharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect AUS-131’s likelihood of approval (LoA) and phase transition for Alzheimer’s Disease took place on 16 Aug 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AUS-131 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

AUS-131 overview

AUS-131 is under development for the treatment of Alzheimer's disease. AUS-131 is administered through oral, topical and parentral route. It is pure, synthetic formulation of the soy metabolite S-equol. The drug candidate targets estrogen receptor beta (ER beta). It was also under development for the treatment of benign prostatic hyperplasia, osteoporosis, hormone refractory prostate cancer, vasomotor symptoms of menopause (menopausal hot flashes) and acne vulgaris, and triple-negative breast cancer.

MEI Pharma overview

MEI Pharma, formerly Marshall Edwards, develops drugs for the treatment of cancer. The company’s drug candidates include pracinostat, an oral histone deacetylase inhibitor, intended for the treatment of advanced hematological diseases including myelodysplastic syndrome; ME-344, a mitochondrial inhibitor intended for the treatment of HER2-negative breast cancer and solid tumors; and Zandelisib (ME-401), an oral PI3K delta inhibitor for relapsed or refractory B-cell malignancies. The company also develops and commercializes Voruciclib, an oral and selective cyclin-dependent kinase (CDK) inhibitor intended for the treatment of acute myeloid leukemia (AML) and B-cell malignancies through an agreement with Presage. MEI Pharma is headquartered in San Diego, California, the US.

Quick View AUS-131 LOA Data

Report Segments
  • Innovator
Drug Name
  • AUS-131
Administration Pathway
  • Oral
  • Parenteral
  • Topical
Therapeutic Areas
  • Central Nervous System
  • Dermatology
  • Male Health
  • Musculoskeletal Disorders
  • Oncology
  • Women’s Health
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.